[go: up one dir, main page]

DK3601358T3 - Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf - Google Patents

Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3601358T3
DK3601358T3 DK18759461.9T DK18759461T DK3601358T3 DK 3601358 T3 DK3601358 T3 DK 3601358T3 DK 18759461 T DK18759461 T DK 18759461T DK 3601358 T3 DK3601358 T3 DK 3601358T3
Authority
DK
Denmark
Prior art keywords
methods
trem2 antibodies
trem2
antibodies
Prior art date
Application number
DK18759461.9T
Other languages
English (en)
Other versions
DK3601358T5 (da
Inventor
Tina Schwabe
Eric Brown
Philip Kong
Seung-Joo Lee
Arnon Rosenthal
Robert Pejchal
Nels P Nielson
Ilaria Tassi
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Application granted granted Critical
Publication of DK3601358T3 publication Critical patent/DK3601358T3/da
Publication of DK3601358T5 publication Critical patent/DK3601358T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK18759461.9T 2017-08-03 2018-08-02 Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf DK3601358T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541019P 2017-08-03 2017-08-03
US201862636095P 2018-02-27 2018-02-27
PCT/US2018/045068 WO2019028292A1 (en) 2017-08-03 2018-08-02 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Publications (2)

Publication Number Publication Date
DK3601358T3 true DK3601358T3 (da) 2023-07-31
DK3601358T5 DK3601358T5 (da) 2024-09-02

Family

ID=63364160

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18759461.9T DK3601358T5 (da) 2017-08-03 2018-08-02 Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf

Country Status (32)

Country Link
US (3) US10676525B2 (da)
EP (2) EP3601358B1 (da)
JP (3) JP2020533948A (da)
CN (3) CN119192376A (da)
AU (1) AU2018311055A1 (da)
BR (1) BR112019022752A2 (da)
CA (1) CA3061755A1 (da)
CL (2) CL2019003093A1 (da)
CO (1) CO2019012210A2 (da)
CR (3) CR20230170A (da)
DK (1) DK3601358T5 (da)
EC (1) ECSP19078429A (da)
ES (1) ES2952982T3 (da)
FI (1) FI3601358T3 (da)
HR (1) HRP20230675T1 (da)
HU (1) HUE062436T2 (da)
IL (2) IL315241A (da)
LT (1) LT3601358T (da)
MD (1) MD3601358T2 (da)
MX (2) MX2019012868A (da)
MY (1) MY201526A (da)
NZ (1) NZ758301A (da)
PE (1) PE20200148A1 (da)
PH (1) PH12019502459A1 (da)
PL (1) PL3601358T3 (da)
PT (1) PT3601358T (da)
RS (1) RS64419B1 (da)
SI (1) SI3601358T1 (da)
SM (1) SMT202300281T1 (da)
TW (1) TWI811229B (da)
WO (1) WO2019028292A1 (da)
ZA (2) ZA201906730B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2015319809B2 (en) 2014-09-28 2020-02-06 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
MX2019012868A (es) 2017-08-03 2019-11-28 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos.
BR112020011833A2 (pt) 2017-12-12 2020-11-24 Pionyr Immunotherapeutics, Inc. anticorpos anti-trem2 e métodos relacionados
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
TW202045543A (zh) 2019-02-20 2020-12-16 美商戴納立製藥公司 抗ｔｒｅｍ２抗體及其使用方法
PH12022551228A1 (en) * 2019-11-22 2023-06-14 Lilly Co Eli Trem2 antibodies and uses thereof
AU2020397888A1 (en) 2019-12-05 2022-06-09 Alector Llc Methods of use of anti-TREM2 antibodies
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
MX2022008582A (es) 2020-01-13 2022-08-10 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
WO2021173565A1 (en) 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies
AU2021247286A1 (en) 2020-04-03 2022-10-20 Alector Llc Methods of use of anti-TREM2 antibodies
CN117396510A (zh) 2021-05-14 2024-01-12 基因泰克公司 Trem2的激动剂
WO2023114499A1 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
AU2023225020A1 (en) 2022-02-23 2024-09-12 Alector Llc Methods of use of anti-trem2 antibodies
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117964768B (zh) * 2024-04-02 2024-06-28 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ES2384942T3 (es) 1996-12-03 2012-07-16 Amgen Fremont Inc. Anticuerpos humanos que se unen específicamente al TNF alfa
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
IL151853A0 (en) 2000-04-11 2003-04-10 Genentech Inc Multivalent antibodies and uses therefor
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
ATE423571T1 (de) 2001-10-12 2009-03-15 Schering Corp Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
EP1508340A4 (en) 2002-05-24 2009-07-01 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
EP1578367A4 (en) 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CA2506672C (en) 2002-12-23 2012-04-17 Schering Corporation Il-23 for treating cutaneous wounds
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
JP2008526205A (ja) 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3167888B1 (en) 2006-03-15 2024-05-01 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US20080247955A1 (en) * 2007-01-16 2008-10-09 Jun Kuai Inflammation treatment, detection and monitoring via TREM-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
WO2009046313A2 (en) 2007-10-05 2009-04-09 University Of Maryland, Baltimore Novel compositions and methods for stimulating erythropoiesis in a mammal
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
RU2580038C2 (ru) 2009-12-04 2016-04-10 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
UY33827A (es) 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
AR087744A1 (es) * 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
AU2015319809B2 (en) * 2014-09-28 2020-02-06 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
JP6955445B2 (ja) 2015-04-07 2021-10-27 ジェネンテック， インコーポレイテッド アゴニスト性の活性を有する抗原結合複合体及びその使用方法
CA2986431C (en) 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
JP2018537956A (ja) * 2015-10-06 2018-12-27 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
KR102415925B1 (ko) * 2016-01-11 2022-07-04 삼성디스플레이 주식회사 표시장치
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
US10941200B2 (en) 2016-07-22 2021-03-09 Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev TREM2 cleavage modulators and uses thereof
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3570883A2 (en) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019021233A1 (en) 2017-07-27 2019-01-31 Novartis Ag TREM2 VARIANTS RESISTANT TO SHEDDASE
MX2019012868A (es) 2017-08-03 2019-11-28 Alector Llc Anticuerpos anti-trem2 y metodos para utilizarlos.
CA3057447A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3681909A1 (en) 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
CN112553210B (zh) 2017-10-03 2024-09-24 普利维尔治疗公司 用于溶酶体障碍的基因疗法
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
BR112020011833A2 (pt) 2017-12-12 2020-11-24 Pionyr Immunotherapeutics, Inc. anticorpos anti-trem2 e métodos relacionados
CN111971397A (zh) 2018-02-14 2020-11-20 耶鲁大学 用于调节trem或treml蛋白的组合物及其使用方法
AU2021247286A1 (en) * 2020-04-03 2022-10-20 Alector Llc Methods of use of anti-TREM2 antibodies
CN117396510A (zh) * 2021-05-14 2024-01-12 基因泰克公司 Trem2的激动剂

Also Published As

Publication number Publication date
EP4248996A2 (en) 2023-09-27
PH12019502459A1 (en) 2020-07-20
CR20230170A (es) 2023-05-31
CO2019012210A2 (es) 2020-04-01
CL2020001974A1 (es) 2020-10-23
JP2023029882A (ja) 2023-03-07
ZA202211057B (en) 2024-02-28
CR20190485A (es) 2020-02-10
MX2019012868A (es) 2019-11-28
TW201912654A (zh) 2019-04-01
AU2018311055A1 (en) 2019-11-14
MY201526A (en) 2024-02-27
HRP20230675T1 (hr) 2023-09-29
JP2024147536A (ja) 2024-10-16
JP2020533948A (ja) 2020-11-26
KR20200033794A (ko) 2020-03-30
ES2952982T3 (es) 2023-11-07
CR20230169A (es) 2023-05-31
IL270235A (da) 2019-12-31
US11634489B2 (en) 2023-04-25
DK3601358T5 (da) 2024-09-02
EP3601358B1 (en) 2023-05-17
EP4248996A3 (en) 2023-11-08
MD3601358T2 (ro) 2023-10-31
WO2019028292A1 (en) 2019-02-07
SI3601358T1 (sl) 2023-10-30
TWI811229B (zh) 2023-08-11
IL270235B1 (en) 2024-10-01
ZA201906730B (en) 2023-04-26
HUE062436T2 (hu) 2023-11-28
NZ758301A (en) 2023-07-28
PL3601358T3 (pl) 2023-10-02
US20190040130A1 (en) 2019-02-07
CN119192377A (zh) 2024-12-27
LT3601358T (lt) 2023-08-10
EP3601358A1 (en) 2020-02-05
CL2019003093A1 (es) 2020-03-20
US10676525B2 (en) 2020-06-09
CN110621696B (zh) 2024-10-25
CA3061755A1 (en) 2019-02-07
IL270235B2 (en) 2025-02-01
PE20200148A1 (es) 2020-01-17
RS64419B1 (sr) 2023-09-29
US20200317776A1 (en) 2020-10-08
BR112019022752A2 (pt) 2020-05-19
PT3601358T (pt) 2023-08-30
CN119192376A (zh) 2024-12-27
FI3601358T3 (fi) 2023-07-20
SMT202300281T1 (it) 2023-11-13
TW202342547A (zh) 2023-11-01
JP7554247B2 (ja) 2024-09-19
CN110621696A (zh) 2019-12-27
IL315241A (en) 2024-10-01
MX2024001803A (es) 2024-03-06
US20230312712A1 (en) 2023-10-05
ECSP19078429A (es) 2020-02-28

Similar Documents

Publication Publication Date Title
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3601358T3 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3551660T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3515478T3 (da) Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3436030T3 (da) Kimæriske receptorer og fremgangsmåder til anvendelse deraf
DK3529257T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3292149T3 (da) Aktiverbare anti-cd71-antistoffer og fremgangsmåder til anvendelse deraf
DK3215532T3 (da) Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
DK3230319T3 (da) Anti-PD-1-antistoffer og fremgangsmåder til anvendelse deraf
DK4063397T3 (da) Kimære antigenreceptorer baseret på enkelt-domæneantistoffer og fremgangsmåder til anvendelse deraf
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3148579T3 (da) Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
DK3390442T3 (da) Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3484916T3 (da) Antistoffer specifikke for hyperphosphoryleret tau og fremgangsmåder til anvendelse deraf
DK3126394T3 (da) Anti-OX40-antistoffer og fremgangsmåder til anvendelse
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf